Correlation Between ZyVersa Therapeutics and Apollomics

Can any of the company-specific risk be diversified away by investing in both ZyVersa Therapeutics and Apollomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ZyVersa Therapeutics and Apollomics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ZyVersa Therapeutics and Apollomics Class A, you can compare the effects of market volatilities on ZyVersa Therapeutics and Apollomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ZyVersa Therapeutics with a short position of Apollomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ZyVersa Therapeutics and Apollomics.

Diversification Opportunities for ZyVersa Therapeutics and Apollomics

0.24

Correlation Coefficient

ZyVersa Therapeutics  Apollomics

Modest diversification

The 3 months correlation between ZyVersa and Apollomics is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and Apollomics Class A in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apollomics Class A and ZyVersa Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ZyVersa Therapeutics are associated (or correlated) with Apollomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apollomics Class A has no effect on the direction of ZyVersa Therapeutics i.e., ZyVersa Therapeutics and Apollomics go up and down completely randomly.

Pair Corralation between ZyVersa Therapeutics and Apollomics

Given the investment horizon of 90 days ZyVersa Therapeutics is expected to under-perform the Apollomics. But the stock apears to be less risky and, when comparing its historical volatility, ZyVersa Therapeutics is 1.03 times less risky than Apollomics. The stock trades about -0.11 of its potential returns per unit of risk. The Apollomics Class A is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  1,013  in Apollomics Class A on December 30, 2024 and sell it today you would lose (252.00) from holding Apollomics Class A or give up 24.88% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

ZyVersa Therapeutics  vs.  Apollomics Class A

ZyVersa Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Apollomics Class A

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apollomics Class A has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with ZyVersa Therapeutics and Apollomics

The main advantage of trading using opposite ZyVersa Therapeutics and Apollomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ZyVersa Therapeutics position performs unexpectedly, Apollomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apollomics will offset losses from the drop in Apollomics' long position.

The idea behind ZyVersa Therapeutics and Apollomics Class A pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.